Who are Fluticasone Furoate/GW642444's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fluticasone-furoate-gw642444.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Fluticasone Furoate/GW642444 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fluticasone Furoate/GW642444 (Fluticasone Furoate/GW642444) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination. Area: Respiratory/Pulmonology.

phase 3 Long-acting inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination Glucocorticoid receptor (fluticasone furoate); beta-2 adrenergic receptor (GW642444/vilanterol) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Fluticasone Furoate/GW642444 (Fluticasone Furoate/GW642444) — GlaxoSmithKline. Fluticasone furoate is a long-acting inhaled corticosteroid that reduces airway inflammation, while GW642444 is a long-acting beta-2 agonist that relaxes airway smooth muscle.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fluticasone Furoate/GW642444 TARGET	Fluticasone Furoate/GW642444	GlaxoSmithKline	phase 3	Long-acting inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor (fluticasone furoate); beta-2 adrenergic receptor (GW642444/vilanterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination class)

GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluticasone Furoate/GW642444 — Competitive Intelligence Brief. https://druglandscape.com/ci/fluticasone-furoate-gw642444. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab